CraniUS Therapeutics Raises $20 Million Series B to Advance NeuroPASS Brain Drug-Delivery Platform

New updates have been reported about CraniUS Therapeutics.

CraniUS Therapeutics has secured $20 million in Series B funding to accelerate development of NeuroPASS™, its fully implantable, skull-embedded platform designed to bypass the blood-brain barrier and enable targeted, programmable drug delivery and monitoring in the brain. The Baltimore-based private neurotechnology company plans to use the new capital to fund regulatory submissions, manufacturing scale-up, and expanded product testing as it moves the platform toward future commercialization, with operating runway expected into 2027. The round follows a $20 million Series A in 2022, bringing total capital raised to approximately $40 million; the latest financing includes $19 million from private investors and $1 million in non-dilutive support from the State of Maryland.

NeuroPASS is being developed as a multi-product platform, initially comprising three complementary devices intended to progressively expand therapeutic capability and shift cranial implants from passive reconstructive hardware to active, long-term therapeutic interfaces suitable for outpatient care. CraniUS, founded by Johns Hopkins neuroplastic surgeon Dr. Chad Gordon, is targeting a core clinical barrier he encountered in practice: patients with severe neurological disease often fail not due to lack of surgical options, but because medicines cannot reliably cross the blood-brain barrier. The company holds 15 issued U.S. patents plus additional international protection underpinning its platform and roadmap. While leadership and board members describe NeuroPASS as a fundamentally new approach to accessing the brain rather than an incremental improvement, the device remains investigational and is not yet cleared or approved by the FDA, with all described uses subject to regulatory review. Executives and investors will be watching how effectively CraniUS converts this new capital into clinical progress, regulatory milestones, and readiness for commercialization across multiple neurological indications.